top of page

PT-141 (Bremelanotide)

Source / Derivation:

​​​

PT-141, also known as Bremelanotide, is a synthetic peptide analog of melanocortin receptor agonists, originally derived from melanocyte-stimulating hormone (α-MSH). It is designed to selectively target central melanocortin pathways involved in sexual arousal and desire

Peptide Mockup (1).png

PT-141 (Bremelanotide)

Mechanism of Action:

​​

PT-141 activates melanocortin receptors (MC3R and MC4R) in the central nervous system, modulating neuronal pathways associated with sexual response. Unlike peripheral vasodilators, it exerts its effects primarily through central nervous system signaling, enhancing sexual desire and arousal.​

​

Clinical Relevance & Potential Outcomes:

​

Clinical studies indicate PT-141 may support improved sexual desire and arousal in both men and women, with a rapid onset of action and a well-characterized safety profile. It has been evaluated as a treatment for hypoactive sexual desire disorder (HSDD) and related sexual dysfunctions.

​

Intended Clinical Application:

​​​

PT-141 may be relevant for patients experiencing reduced sexual desire or arousal, particularly in cases of hypoactive sexual desire disorder or related clinical conditions.

Formulation & Quality Specifications:

​

  • Delivered as a liquid prefilled pen

  • Purity: >98% (HPLC-validated)

  • Storage: 2–8 °C (refrigerated)

  • Documentation: Full CoA and MSDS available

Concentration:​

5 mg/ml, total 3 ml, total 15 mg

Frequency:

As required

Dosage (pen clicks):

Primary Dose: Take 5 (units) approximately 3-4 hours before sexual activity. Boosting Dose: To enhance the effect, an additional 5 (units) can be taken immediately before sexual activity.

Duration:

1 month​

Notes:

A selective growth hormone secretagogue that stimulates GH release without increasing cortisol or prolactin, supporting muscle growth and recovery​.

bottom of page